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Since the discovery by Landsteiner (1, 2) that low molecular weight haptens
would react with antihapten antibody to inhibit precipitation by azoprotein
antigens, and of Marrack and Smith (3) that binding of haptens to antibody
could be demonstrated by equilibrium dialysis, such interactions have been used
for identifying antigenic determinants and for establishing specificities andsizes
ofantibody combining sites (cf. 4, 5).
Specificities for carbohydrate antigens often appear to be directed toward the structure
and linkage of terminal nonreducing sugars. This was first recognized by Goebel, Avery,
and Babers (6), who found that the structure of the terminal nonreducing sugar was of
predominant importance in determining cross-reactions with rabbit antisera to various
disaccharides conjugated to horse serum globulin. Later, Karush (7) showed that
lactoside-specific rabbit antibodies, produced by immunization with a lactosyl-azoprotein
conjugate, had the major portion of their binding energies directed against the terminal
,d-linked galactose. With glycoproteins and polysaccharides there are many examples of
terminal antigenic determinants. These include the A, B, H, and Lewis specificities of
human blood group substances (8, 9), terminal glucuronic acid residues which are
involved in the specificity ofType II pneumoccous polysaccharide (10-13 cf. 4, 5, 14), and
terminal fl-N-acetylglucosamine for Group A (15) and a-N-acetylgalactosamine for Group
C (16) specificities in streptococcal polysaccharides (cf. 17). Certain determinants in
teichoic acids (17-21 cf. 22) and in the somatic antigens of Salmonella (23, 24) and
Shigella (25) are also of this type.
Antigenic determinants which do not require a terminal end group have also been
recognized. Polysaccharides such as the type III and VIII pneumococcal polysaccharides
which were shown to be linear (26) and thus to have one nonreducing end per milecule had
long been known to precipitate with homologous antisera and also to cross-react (cf. 4) .
The determinant of the Type III polysaccharide (S III) was shown to consist of three
repeating units of the disaccharide, cellobiuronic acid (27) . Moreover, Heidelberger and
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Rebers (28) attributed the cross-reactivity between anti-S IV sera and S II to (1 --a
3)-linked L-rhamnose units which occur at intervals along linear sugar chains . Nontermi-
nal determinants are important in Shigella (25) and Salmonella (24), examples being deter-
minants 3 and 15 of group E Salmonella which involve repeating [a D Gal(1-6)D Man-
(1-4)L Rham(1--,3) ] sequences (29) . In addition, certain specificities for teichoic acids
(30 cf. 22) are of this type. It has been suggested that steric factors play a role in the proper
exposure of certain terminal (31-33) and nonterminal (34) sugar determinants .
Dextrans are branched polymers of a-linked D glucopyranosyl units and their relatively
simple structures have made them especially useful in immunochemical studies of
homopolysaccharide antigens. Specificities involving all -" 6)- and all - 2)-, all - 3)-,
all - 4)-linked D glucopyranosyl units have been described (35-43). The reactions of all
6) -specific antidextrans have been thought to occur at the nonreducing ends of glucose
chains with the terminal all - 6)-linked D glucopyranosyl residue being immunodomi-
nant. The evidence for this has come from the structure of these polysaccharides which
have several nonreducing ends but only one reducing end, and from inhibition of precipi-
tation studies with isomaltose oligosaccharides from which it appeared that a majority
of the binding energy was contributed by the terminal nonreducing glucose (44, 45, cf.
4, 5) . In addition, rabbits which had been immunized with bovine serum albumin (BSA)'
conjugates of isomaltotrionic acid (IM3-CONH-BSA) (46), and isomaltohexaonic acid
(IM6-CONH-BSA) (47), produced antibodies whose quantitative precipitin reactions
with dextrans were similar to those of all - 6)-specific antidextrans. However, the best
inhibitor for certain rabbit sera to IM3-CONH-BSA was larger than the trisaccharide
which suggested as one possibility that specificities for nonterminal antigenic determi-
nants such as (-0-(1 - 6)-D Glc-a-0-) sequences might exist (46) . Moreover, Richter (48)
has shown that rabbit antibodies to a dextran-protein conjugate made with a dextran frag-
ment of mol wt 4,400 could precipitate a synthetic linear dextran (49, 50) which implied
that these antibodies were capable of reacting with nonterminal glucosyl residues. Con-
canavalin A, which is thought to react at terminal nonreducing ends of dextran chains,
does not precipitate with synthetic linear dextran (51). These findings raise two questions
of fundamental importance: (a) Are antidextrans and antibodies against isomaltosyl oligo-
saccharides coupled to protein, mixtures of antibodies with specificities directed toward
terminal nonreducing as well as nonterminal oligosaccharide sequences? (b) Can anti-
bodies against terminal determinants cross-react at nonterminal locations along the dex-
tran chain?
The existence of several homogeneous BALB/c mouse myeloma proteins with specifici-
ties for dextrans (52-55), fructosans (54-56), and galactans (57-59) provides a very useful
approach to these questions . Three dextran-reactive myeloma globulins, W3129, W3434
and QUPC 52, have been shown (55) to have all -+ 6) specificities . Proteins W3129 and
W3434 differed slightly in specificity (55) and idiotype (60), but both showed maximum
complementarity to isomaltopentaose (IM5) while protein QUPC 52 showed maximum
binding for isomaltohexaose (IM6) and was not related idiotypically to W3129.
We have now determined the binding energies for the interactions of proteins
W3129 and QUPC 52 with each member of the isomaltose series and with methyl
aDglucoside. These results indicate the protein W3129 has a nonreducing
terminal specificity for ce(1 - 6) chains of dextran while protein QUPC 52 has
nonterminal specificity . This was confirmed by precipitin reactions with a
synthetic linear dextran which failed to precipitate protein W3129 but precipi-
tated QUPC 52 . The correlation between the binding properties of these
myeloma proteins and their precipitin reactions with the synthetic dextran (49,
50) provides further evidence that this dextran reacts immunochemically as aJ. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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completely linear molecule. In addition, quantitative precipitin studies with
linear and branched dextrans favor the concept that some human antidextran
molecules also react only at terminal nonreducing ends while others can react at
nonterminal locations along linear dextran chains. Moreover, rabbit antisera
against IM3 or IM6 coupled to BSA' contain fractions of molecules which
precipitate linear dextran and thus must be capable of nonterminal reactions
with dextran chains. These findings provide a fundamental insight into the
immunochemistry of dextran and probably other polysaccharide antigens .
Materials and Methods
Human and Rabbit Antisera and Mouse Myeloma Proteins.
￿
Human antidextrans are listed in
Table I along with the dextrans employed for immunization . Serum 1 D.,.,, was a pool obtained by
plasmapheresis of subject 1 seven times over a period of 2 mo, and was taken 18 1/2 years after
immunization with dextran B1255. Rabbit antisera against IM3-CONH-BSA (46) and IM6-CONH-
BSA (47) were those studied previously. BALB/c mouse IgA myeloma proteins W3129, QUPC 52,
W3082, and UPC 61 have been described (55) and were from serum or ascites fluid generously
provided by Doctors Melvin Cohn and Martin Weigert (The Salk Institute, San Diego, Calif.), and
Dr. Michael Potter of NIH.
Purification of HumanAntidextrans and MouseMyeloma Proteins .
￿
Purification of antidextrans
and myeloma proteins was by a standard batch-wise immunoadsorption procedure (63-65) using
Sephadex G75 (Pharmacia Fine Chemicals, Inc ., Piscataway, N. J.) for human antidextrans and
proteins W3129 and QUPC 52 andlevan gel (66, 68, 69) for humanantilevans and proteins W3082and
UPC 61 . After adsorption of protein, the insoluble gels were washed with 0.01 M phosphate-buffered
saline, pH 7.2, 0 .02% sodium azide (PBS) until supernates gave negligible absorption at 280 nm.
Hapten elution was at 37°C for 1 h and proteins were freed of hapten by at least two passes through
columns of Bio-Gel P-10 (Bio-Rad Laboratories, Richmond, Calif.) (68, 69) and concentrated by
ultrafiltration with collodion bags (Schleicher & Schuell, Inc., Keene, N. H.) or above a Diaflow
UM-10 membrane (Amicon Corporation, Lexington, Mass .).
Antidextrans from 3,726 ml of 1 D,,-,o which contained 15.1 mg antidextran nitrogen (N) were
adsorbed on to 922 mg Sephadex G75 and eluted with IM3 and IM6 in a batch-wise modification of
the procedure described by Harisdangkul andKabat (68) . Thepacked Sephadex G75 waseluted first
with 270 mg of IM3 in 15 ml PBS. This eluate (1 D_ IM3El 1) was concentrated and the
ultrafiltrate containing most of the IM3 was used for the second IM3 elution and after this, the
process was repeated a third time. TheSephadex wasthen washed with PBS and the washings were
combined with the second andthird IM3 eluates to give 1 DS,-, o IM3E12-3. Then 202mgIM3 in 15 ml
PBS were added to the packed Sephadex and this eluate plus the next two were combined to give 1
D6,_BO IM3E1 4-6. The washed Sephadex was then extracted six times as above starting with 90 mg
IM6 in 15 ml PBS and these were pooled to give 1 D,,_,p IM6E1 1-6. The total recovery from all
elutions was 10 .2 mg antidextran N (68%) of which 1 D5,_ IM3E1 1, El 2-3, El 4-6, and IM6E1 1-6
accounted for 52, 21, 8, and 19% respectively. After removal of antidextrans, human antilevans were
purified from 1 D5,_ sera by elution from levan gel with 0.1 M acetate buffer, pH 3 .7 (66, 68).
Dextran- and fructosan-specific mouse myeloma proteins were eluted with methyl anglucoside
and sucrose respectively, which had previously been dialyzed to remove polysaccharides (70) and
recrystallized from ethanol. With protein W3129, 45.5 mg of myeloma N was adsorbed to 4 g of
Sephadex G75, and eluted three times with about 200 mg methyl a nglucoside per mg of myeloma N;
the final recovery was 36 mg W3129 N (79%) . With protein QUPC 52, 92 mg of myeloma N was
adsorbed to 6.3 g of Sephadex, washed, and eluted 10 times with methyl anglucoside at about
420 mg methyl anglucoside per mg of myeloma N; the final recovery was only 26 mg QUPC 52 N
(28%). The G75 was then eluted repeatedly in the cold (30 min per elution) with 0.1 M glycine HCI
buffers ranging from pH 3.0 to pH 1.8 and eluates were neutralized immediately after collection. The
`Abbreviations used in this paper: BSA, bovine serum albumin; IM2, isomaltose; IM3,
isomaltotriose; IM4, isomaltotetraose; IM5, isomaltopentaose; IM6, isomaltohexaose; IM7, isomal-
toheptaose; PBS, phosphate-buffered saline.438
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TABLE I
Human Antidextrans
final yields were: 2.4 mg N at pH 3.0 (one elution) 11.8 mg N at pH at pH 2.7 to 2.4 (four elutions),
13.7 mg N at pH 2.0 (three elutions), and 4.6 mg N at pH 1.8 (three elutions) giving a total recovery
in the low pH elutions of 32.5 mg QUPC 52 N (35%) . All eluates were between 90 and 95% reactive
with Sephadex G75. With proteins W3082 andUPC 61, 1.2 mg myeloma N wasadsorbed onto 65 mg
levan gel and eluted twice with 300 mg sucrose per mg myeloma N which removed virtually all ad-
sorbed protein.
Dextrans.
￿
Native dextran B512 and clinical dextran N-150N have been described (61 cf. 4) . Prof.
Conrad Schuerch, Chemistry Department, State University College of Forestry, Syracuse, N. Y.,
kindly provided dextran D3 which by chemical methods appears to be a completely linear polymer of
a (I - 6)-linked D glucopyranosyl units having a mol wt by viscosity of 36,500 (49, 50). Enzymatic
degradation experiments indicate that synthetic dextran contains 1-2% of structural flaws (71).
Qligosaccharides. The isomaltose oligosaccharides, methyl anglucopyranoside, the ,B (2
1)-linked series of fructose oligosaccharides and sucrose were those described (55) . Methyl
a-isomaltoside andmethyl a-isomaltotrioside (72) were provided by Dr. Allene Jeanes andhave been
studied previously (4, 65) .
Tritium-labeled isomaltoheptitol Q1H]IM7-OH) was prepared by overnight reduction at 4°Cof 90
umol IM7 with 25 gmol [8111 sodium borohydride (383 mCi/nmol), andthe reaction was stopped by
adding small amounts of 25% acetic acid. The partially reduced and tritiated IM7 was then
completely reduced with a 20-fold molar excess of NaBH,. After 2 days at 4°C, excess NaBH, was
destroyed and the [IHIIM7-OH was purified by ethanol elution from a charcoal-celite column,
followed by preparative paper chromatography with a propanol-ethanol-water (6:1 :3) solvent system
andfinal chromatography on a Bio-Gel P-2 column (minus 400 mesh, 70 x 1 .9 cm) (73) .
Immunochemical Methods . Quantitative precipitin and inhibition assays were done by a
microtechnique (4) and total N in the washed precipitates was measured by the ninhydrin method
(74). The separation of IgA monomer and polymer fractions of protein QUPC 52 and quantitative
immunoadsorption experiments with dextran-reactive proteins using Sephadex G75 were like those
described for protein W3129 (55) .
Isoelectric Focusing.
￿
Analytical isoelectric focusing in a thin layer of 5% polyacrylamide gel (3%
cross-linked) containing 2% carrier ampholytes (ampholine pH 3.5-10) was performed with an LKB
2117 Multiphor unit according to the directions of the manufacturer (LKB-Producter AB, Sweden).
Gels were fixed overnight in 12% trichloroacetic acid then rinsed in several changes ofwater to remove
carrier ampholytes before staining with 0.02% Coomassie Blue in methanol-acetic acid-water
(45:9:46) and destaining with a solution of methanol (25%) and acetic acid (10%) . Preparative
Antidextran
Immunizing
dextran
all-~ 6)
Linkages
a(1-3)-
like
a(1- 4)-
like
Reference
ID,+_e0 B1255 86 0 14 4, 5, 36, 37, 45, 61, 63, 65,
(Native) 66, 67, 68
201),o OP 155 88 4, 5, 36, 44, 45, 61, 63, 64,
(Clinical) 65, 66, 67
30D, OP 163 88 4, 5, 35, 36, 37, 44, 45, 61,
(Clinical) 66,67
116D, S-5-A-1 .0 86 10 4 4,37
(Clinical)
176D, NRC Fr. 4 96 4 0 4, 5, 45, 62, 64
(Clinical)
219D, APC-54 62
(Clinical)J. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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isoelectric focusing of 1 D-,o IM3El 2-3 (1.6 mg N) was done in a 110ml LKBcolumn at 4°C using
3% carrier ampholytes (pH 3.5-10) in a sucrose gradient as described by the manufacturer.
Electrofocusing was for 3 days with a final potential of 700 V.
Equilibrium Dialysis.
￿
Equilibrium dialysis and displacement experiments were carried out in
lucite microdialysis chambers (75) at 25°C f 0.1 °andPBSwasthebuffer in allexperiments. Dialysis
tubing was boiled in 2 M Na,CO, and rinsed thoroughly before use. Control experiments (4)
established that therewasno detectable bindingoftheligand [9H]IM7-OHto thedialysis membrane,
to normal human -y-globulin (4.1 mg/ml) or to the levan-reactive IgA mouse myeloma protein Y5476
(14 mg/ml) (55). Experiments were done with equal volumes (50 or 75 u1) on each side of the
membrane and dialysis cells were allowed to reach equilibrium over a 72-h period of continuous
mixing; however, displacement experiments with protein QUPC 52 were given an extra daybecause
of the high concentrations of competitors employed. Control experiments indicated that equilibrium
wasprobably attained in less than 24 h. Samples (20 ,l) forradioactivity measurements were taken
from thehapten side only (76) andcounted in duplicateor triplicate. The [9H]IM7-OH gave about2.9
x 10° cpm/,mol in Bray's solution (77) and 3.5 x 10° cpm/,umol in Insta-Gel (Packard Instrument
Co., Downers Grove, Ill.). In displacement experiments, nonlabeled competitors did not cause any
detectable quenchingofcounts except forthehighest amountsof methyl a Dglucoside employed with
protein QUPC 52 andthis occurred only in Insta-Gel and was correctedfor. The free concentration of
competitor was calculated by the method of Nisonoff and Pressman (78).
Fluorescence Titrations.
￿
Fluorescence titrations were performed with square quartz semimicro
cuvettes (5 mm light path, 0.6 ml capacity) and an Aminco-Bowman spectrophotofluorometer
equipped with a cell jacket thermostated at 25°C (68) . Haptenswere added in 5-20,ul volumesto 250
,ul portions of protein solutions having optical densities of about 0.18 (1 cm light path) at 280 nm.
None of thehaptens absorbed in the 280 nm region and the excitation wave length was set between
280 and 285 nm depending on the protein and emission was measured between 345 and 350 nm.
Values for Q... were determined at the end of each titration by averaging the results from two
additions of a concentrated ligand solution, each resulting in a greater than 97% saturation of sites.
All titrations were done against areference cell containing thesolution beingtitrated and in this way
it was possible to detect andcorrect for instrument drift. It was also necessary to plan experiments so
that each addition of hapten resulted in at least a 3% quenching of fluorescence aftercorrection for
dilution.
Results
Isoelectric Focusing of Human Antibodies. Purified antidextrans from 1
D5,-60 were 90-95% reactive with Sephadex G75 and analytical isoelectric
focusing revealed a restriction in heterogeneity as compared with whole -y-
globulin from the same individual. The patterns forantidextrans eluted with IM3
(Fig. 1 A,IM3El 1, IM3E1 2-3, and IM3E1 4-6) were similar with three major
bands near pH 7.0 and several less prominent bands between pH 6.0 and pH 8.5.
The antidextrans eluted with IM6 (Fig. 1 A, IM6E1 1-6) were qualitatively like
the IM3 eluates, but the three major bands near pH 7.0 were less obvious while
those between pH 7.0 and pH 8.0 accounted for a greater proportion ofthe total
protein. Purified antilevan from 1 D,60 (Fig. 1 A, L) and antibodies to blood
group A substance from 1 D33-a, (Fig. 1 A, A) also were restricted in heterogeneity
and visibly different from each other and from the 1 D54-60 antidextrans. The
anti-A antibodies hadrelatively low isoelectric points . A pH 3.5to pH 10gradient
was used for the preparative separation of 1 Ds,-6o IM3E1 2-3 into seven fractions
(Fig. 1 B and C) which were studied later.
Equilibrium Dialysis of Mouse Myeloma Proteins and Human Antidextrans.
Purified BALB/c mouse myeloma proteins W3129 and QUPC 52 were approxi-
mately 95% reactive with Sephadex G75, had two binding sites for [3H)IM7-OH
per IgA monomer, and gave linear Scatchard plots indicating homogeneous bind-440
￿
BINDING PROPERTIES OF IMMUNOGLOBULIN COMBINING SITES
FIG. 1 .
￿
A. Analytical isoelectric focusing of 7-globulin ( ,yG) and purified antibodies from
subject 1 . Antidextrans from 1 D5,_ eo were those eluted from Sephadex G75 by sequential
extraction with IM3 (IM3 eluate 1, IM3 eluate 2-3, and IM3 eluate 4-6) then IM6 (IM6 eluate
1-6) . The antilevan (L) from 1 D,,_ 8, and anti-blood group A antibodies (A) from 1 D-yG
fraction of Ga1NAc eluate (79) are shown. Approximately 5.2 Ag Nof all samples were applied
to the gel . (B) Preparative isoelectric focusing of 10 mg 1 D6,-eo IM3 eluate 2-3 showing how
fractions I to VII were collected . (C) Analytical isoelectric focusing of 1 D,,-,,IM3 eluate 2-3
andfractions I to VIIfromB. Approximately3.3 kgNof all samples were applied to the gel .ing (Fig. 2 A), as did the heterogeneity indices of 1.0 from Sips plots (not shown)
for protein QUPC 52 and 0.9 for W3129. Both proteins were mixtures of mono-
meric and polymeric IgA, and the homogeneous binding shows that polymeriza-
tion of IgA monomers does not alter the binding constants toward monovalent
haptens. The binding constant of protein W3129 (K11 = 1.0 x 105 M- ') was about
10-fold greater than that of protein QUPC 52 (K11 = 8.4 x 103 M- ').
As expected from their isoelectric focusing patterns (Fig. 1 A), binding of
[3H]IM7-OH by human antidextrans 1 D5,-1111 IMM 1 and 1 De,-s11IMM 1-6 was
heterogeneous as revealed by nonlinear Scatchard plots (Fig. 2 B). From Sips
J. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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FIG. 2.
￿
Scatchard plots of equilibrium dialysis data at 25°C with ['Hlisomalthoheptitol. (A)
Protein W3129 (") at 10.5 mg/ml, and protein QUPC 52 (O) at 20.6 mg/ml. (B) Purified
human antidextrans, 1 D_ IM3 eluate 1 (O) at 6.68 mg/ml, and 1 D,,_,o IM6eluates 1-6 (")
at 2.56 mg/ml. Calculations were done with a mol wt of 150,000 for myeloma proteins and
human antidextrans .
analyses (not shown) heterogeneity indexes of 0.6 were calculated for both the
IM3 and IM6 antibody. Association constants for 1 D5,-1111 IMM 1 (K11 =1.1 x 105
M-') and 1 Ds,-611 IMM 1-6 (K11 =1.8 x 105 M- ') differed slightly and were
similar to the value obtained for myeloma protein W3129.
Equilibrium Dialysis Displacement Studies with Myeloma Proteins W3129
and QUPC 52. Association constants for isomaltose oligosaccharides and
methyl aDglucoside were determined by measuring the abilities of unlabeled
oligosaccharides to displace [3H]IM7-OH from the binding sites of proteins
W3129 and QUPC 52. For both proteins, displacement curves with IM6 and IM7
were the same as self displacement curves calculated (78) for [3H]IM7-OH and,
thus, the association constants for IM6 andIM7 with proteins W3129 and QUPC
52 are 1.0 x 105 M-' and 8.4 x 103 M-' respectively. With each protein, a442
￿
BINDING PROPERTIES OF IMMUNOGLOBULIN COMBINING SITES
displacement curve was calculated for a hypothetical competitor withK=1M-1
and thus a AF' = 0 cal/mol (8F0 = -2.303 RT log K), and this serves as a use-
ful reference as the distance between it and the displacement curve of a given
competitor is directly proportional to the AF' forthe competitor .
With protein W3129 (Fig . 3A and Table II) over half of the binding energy for
IM6 and IM7 is directed against methyl aDglucoside or IM2 which are similar.
These are much less active than IM3 or IM4 which are equal and are bound
almost as firmly as longer oligosaccharides . Isomaltopentaose is most efficient
at displacing [3H]IM7-OH'and even somewhat more active than IM6 or IM7.
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FIG. 3 . Equilibrium dialysis displacement at 25°C of ['Hlisomaltoheptitol by unlabeled
isomaltose oligosaccharides and methyl aDglucoside . (A) Protein W3129 (10.5 mg/ml) with a
concentration of ['H]isomaltoheptitol giving r = 0.62 in the absence of competitor . (B) Protein
QUPC 52 (20.6 mg/ml) with a concentration of ['H]isomaltoheptitol giving r = 0.39 in the
absence of competitor. The dashed displacement curve corresponds to a hypothetical
competitor with Ke = 1M- `. The dashed horizontal line signifiedthe concentration of bound
['H]isomaltoheptitol in the absence of competitor .
Thus, while maximum complementarity is for IM5, 91% of the total binding
energy is directed toward IM3 and 56% is for methyl aDglucoside .
The pattern of displacement reactions for protein QUPC 52 (Fig . 3Band Table
II) were strikingly different than those ofmyelomaW3129. Most significant were
the findings that displacement by methyl aDglucoside and IM2, which could not
be studied at higher concentrations than those shown in Fig . 3 B, were close to
the hypothetical displacement curve having K=1M-1 , and these competitors
were bound at QUPC 52 sites with only about 5% of the total binding energy for
IM6 or IM7 (Table II) . By contrast, IM3 was much more active and 72% of the
total binding energy was directed against thetrisaccharide . There were increasesR
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BINDING PROPERTIES OF IMMUNOGLOBULIN COMBINING SITES
in binding energy between IM3 and IM4 and from IM4 to IM5. IM5 seemed to be
slightly less active than IM6 or IM7 but this difference, although known to exist
from inhibition studies (55) is so small that it probably is within experimental
error in the present data. Thus, maximum complementarity is for the hexasac-
charide, and while 72% of the total binding energy is for IM3, almost none of this
can function in the binding of IM2 or methyl a D glucoside.
Fluorescence Studies with Mouse Myeloma Proteins and Human Antidex-
trans. The binding of isomaltose oligosaccharides and methyl a D glucoside by
protein W3129 was associated with a quenching of the protein's fluorescence and
Q,,,. values from several titrations varied from 16 to 20% with IM3 through IM7
and from 20 to 23% with IM2 and methyl a D glucoside. The binding data (Fig. 4
A) from fluorescence titrations are in good agreement with results from
equilibrium dialysis displacement and from quantitative precipitin inhibition
assays (Table U) . However, one difference was that IM5, IM6, and IM7 gave
similar association constants in fluorescence titrations while in equilibrium
dialysis displacement IM6 and IM7 were less active than IM5. Both methods
show that maximum binding occurs with IM5 and gave similar Ko values for its
binding by protein W3129. Titrations with monomer and polymer fractions (not
shown) gave the same results as with unfractionated W3129 and supported the
previous conclusion that polymerization of IgA subunits does not effect binding
of a monovalent hapten. Compounds other than isomaltose oligosaccharides also
PROTEIN W.3129
- PROTEINS W3082 and UPC61
I
￿
I
￿
1
￿
1
￿
I
-4 .0 -3,0 -2 .0 -I .0 0
LOG C (M)
FIG. 4 . (A) Sips plots of data from fluorescence titrations at 25°C of dextran-specific
myeloma protein W3129 with isomaltose oligosaccharides and methyl anglucoside (symbols
as in Fig. 3) and of (B) fructosan-specific myeloma proteins W3082 and UPC 61 with IB (2 --.
1)-linked fructose oligosaccharides (2FlG and 3F1G) and with sucrose. All proteins were at
20 fag N/ml, andthe excitation and emission wave lengths with W3129 were 280 and 345 nm
respectively, and 285 and 345 nm respectively with W3082 and UPC 61 .J. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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quenched the fluorescence of protein W3129, but with these it was often not
possible to reach Q.... By using QMRX obtained from adding IM5, association
constants were estimated for the a (1 -" 2), a (1 -" 3), and a (1-+ 4) -linked glucose
disaccharides, kojibiose, nigerose, and maltose, respectively, as being between
102 M-1 and 103 M-', and were lower than those of IM2 and methyl aDglucoside.
Methyl #Dglucoside, methyl aDglucoside, methyl aDmannoside, trehalose (aD-
glucopyranosyl aDglucopyranoside) and glucose all had K,, values less than 5 x
10' M-'. These findings emphasize the specificity which the W3129 site has for
isomaltosyl structures. The binding of isomaltose oligosaccharides by protein
QUPC 52 was not associated with a change in fluorescence .
The fructosan-specific myeloma proteins W3082 and UPC 61 (55) were
indistinguishable and had Qmax values from 6 to 9% with the tetrasaccharide
MG, 5 to 7% with the trisaccharide 2F1G, and 10 to 13% with sucrose. Both
proteins had association constants of 3.6 x 105 M- ' with 3FIG and 2F1G and 6.3
x 102 M-' with sucrose (Fig. 4 B and Table II). Thus, 50% of the total binding
energy was directed against the nonreducing, ,Q-linked, fructosyl unit of sucrose
which represents the immunodominant group. The oligosaccharides 2FIG and
3FIG present two and three fructosyl units respectively in # (2 , 1) linkage plus
an additional ,B linkage and were similar, although earlier studies (55) showed
that 3FIG was slightly more active than 2F1G (Table II). In the fluorescence
data this small difference would be expected to be within experimental error.
Purified human antidextrans were then assayed for changes in fluorescence
associated with the binding of IM5 and IM7 and fluorescence enhancement was
found with all fractions tested. Qmex values for 1 D5,_so IM3E1 1 and El 2-3 were
between 9 and 11%; however, with 1 D,so IM6El 1-6, Qm.X was only 4% and thus
differed significantly from the IM3 eluates. Fractions II through VI from
isoelectric focusing of 1 D5,_ga IM3E12-3 (Fig. 1 B and 1 C) were then assayed and
Qma. values for fluorescence enhancement were 6, 5, 8, 17, and 17% respectively.
Thus, there was a significant difference between fractions II, III, and IV
compared with fractions V and VI .
Quantitative Inhibition Assays with Myeloma Proteins and Human Antidex-
trans. The binding of oligosaccharides by human antidextrans and the mouse
myeloma proteins was compared further by quantitative inhibition assays . The
dashed inhibition curves in Fig. 5 correspond to a hypothetical inhibitor with
Ko = 1 M- ` (AF' = 0 cal/mol) and their positions were calculated from binding
constants obtained from equilibrium dialysis (cf. Fig. 2) . With the IM3 and IM6
eluates of 1 D5,_BO (Fig. 5 A and B, respectively), approximately 20% of the
binding energy for IM7 is for methyl a D glucoside while the corresponding values
for the myeloma proteins are 56% for W3129 (Fig. 5 C) and close to 0% for QUPC
52 (Fig. 5 D) . Large amounts of methyl aDglucoside (> 10% wt/vol) were
required to inhibit precipitation of the human antidextrans and some inhibition
could have been nonspecific. Indeed, the relatively steep slopes of these
inhibition curves and the finding that fructose gave inhibition in the same range
(Fig. 5 A and B) suggest that methyl aDglucoside may actually be bound by the
human antidextrans with less than 20% of the total binding energy . Isomaltose
was a much more effective inhibitor of the human antidextrans than was methyl
aDglucoside and the disaccharide was bound by the IM3 and IM6 eluates with446
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67 and 56% of their total binding energies, respectively. By contrast, IM2 and
methyl aDglucoside were similar with proteins W3129 and QUPC 52. Methyl
a-IM2 was then assayed to determine if closing the reducing glucose in IM2 could
increase its molar inhibitory power to that of IM3. With thehuman antidextrans,
methyl a-IM2 and IM2 gave the same amount of inhibition on a molar basis, but
with protein W3129, methyl a-IM2 was intermediate between IM2 and IM3. It
was not possible to use large enough amounts of methyl a-IM2 to reach 50%
inhibition with protein QUPC 52 but the results indicated that methyl a-IM2
was much less active than IM3. The binding of IM3 contributed 80% of the total
binding energy with the 1 D5,_so IM3 antidextrans, 69% with the 1 D54_so IM6
antidextrans, 94% with protein W3129, and 64% with protein QUPC 52. Methyl
a-IM3 and IM3 had similar molar inhibitory powers with protein QUPC 52 and
both were less active than IM4. With the myeloma proteins the conclusions from
inhibition studies were in good agreement with those from equilibrium dialysis
and fluorescence titrations (Table II). Although the IM3 and IM6 eluates of 1
DS4_so are heterogeneous, it seems likely that these antibodies differ from either
myeloma protein in that the greatest increase in binding occurs between methyl
anglucoside and IM2.
Quantitative Precipitin Studies with Branched and Linear Dextmns.
￿
Quan-
titative precipitin reactions for proteins W3129 and QUPC 52 with branched
dextrans B512 (mol wt > lOs) and N-150N (mol wt = 60,000) and with linearW
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z
Q
0
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dextran D3 (mol wt z- 36,500) were then determined. Protein W3129, containing
monomeric and polymeric IgA (Fig. 6, I a) and a polymer-rich fraction of W3129
(Fig. 6, I b) reacted well with the branched dextrans but did not precipitate with
linear dextran D3. Moreover, quantitative inhibition assays indicated that
dextran D3 and IM5 were similar on a molar basis, in their abilities to inhibit
precipitation of W3129 by native dextran B512. Protein QUPC 52 containing
monomeric and polymeric IgA precipitated best with dextran B512 and less but
equally with the low molecular weight branched dextran, N-150N and linear
dextran D3 (Fig. 6, I c). After separation of QUPC 52 into polymeric and
monomeric forms, the polymer-rich fraction precipitated almost as well with
dextrans N-150N and D3 as with native dextran B512 (Fig. 6, I d). The
monomer-rich fraction of QUPC 52 gave significant precipitation with native
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Quantitative precipitin curves with native, clinical and linear dextrans and mouse
myeloma proteins (I a to d), human antidextrans (I e to g), purified antidextrans from 1 D6,.eo
(II a to d), fractions from isoelectric focusing of 1 D,,_,o IM3 eluate 2-3 (II e to k), and rabbit
antisera against IM3-CONH-BSA (III a to e) and IM6-CONH-BSA (III f to k) .448
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dextran B512 but almost no precipitation with dextrans N-150N and D3,
respectively (Fig. 6, 1 d) . Thus, with protein QUPC 52, as was shown for protein
W3129 (55), the decreased precipitation of myeloma protein by clinical as
compared with native dextran results from the monovalent reaction of IgA
monomers with dextran molecules. Monovalent binding of monomers inhibits
precipitation of polymeric IgA more so with low molecular weight dextrans than
with high molecular weight dextrans whichcontain a greaternumber of antigenic
determinants per molecule (37, 61 cf. 4) .
With individual human antidextrans the fraction of antibody precipitated by
linear dextranD3 compared with that precipitated by native dextranB512 was at
least 90% for 1 D,2 (Fig . 6,1 e), 66% for 20 D,, (Fig . 6, I f), 71% for 30 D, (Fig . 6, I
g), and 73, 80, and 48% for 116 D,, 176 D,, and219 D, respectively (not shown) . In
addition 20 D,o serum, after absorption with linear dextran Da, could still
precipitate branched dextran B512 . With the IM3 and IM6 eluted antidextrans
from 1 D,,-BO (Fig. 6, II a to d), the data suggest that the IM3 eluates but not the
IM6 eluates precipitate somewhat better with B512 than with D3 although the
differences are slight . The fractions from isoelectric focusing of 1 D,,_so IM3
eluates 2-3 were also studied (Fig . 6, If e to k), and with the possible exception of
Fr . II, all fractions precipitated the same with dextrans B512 and D3. Unfrac-
tionated 1 D5,-,, IM3E1 2-3 (Fig. 6, II b) was 88% precipitable with dextran B512
while the fractions from isoelectric focusing were less than 50% precipitable . No
attempt was made to determine the activity of recombined fractions. Thus, the
antidextrans from subject 1 react almost equally with linear and branched
dextran, but with subjects 20, 30, 116, 176, and 219 there are clear differences in
the amounts of antibody precipitated by linear dextran D3 and native dextran
B512 .
Five rabbit antisera (R-25, to R-29,, Fig. 6, III a to e) against IM3-CONH-BSA
were studied and the fractions of antibody precipitated by dextran D3 compared
with dextran B512 were 38, 33, 37, 38, and 28% respectively. With six rabbit
antisera against IM6-CONH-BSA (R-47, to R-52,, Fig. 6, III f to k) the
corresponding fractions of antibody precipitated by dextran D3 were 39, 28, 44,
59, 44, and 52% respectively. Clinical dextran N-150N and linear dextran D3 re-
acted in a similar fashion with the various rabbit antisera .
Discussion
The present findings demonstrate a new parameter in the immunochemistry of
homopolysaccharide antigens. Binding data for myeloma proteins W3129 and
QUPC 52 show clearly that protein W3129 reacts only at terminal nonreducing
ends of dextran chains, and that protein QUPC 52 can react at nonterminal
locations along linear a (1 ---> 6) -linked dextran chains. An understanding of how
these different reactivities manifest themselves in immunochemical data should
aid greatly in understanding the immunochemistry of dextrans. It strongly
supports the concept that antidextrans induced by immunization are generally
mixtures of molecules, some with terminal and others with nonterminal specifici-
ties . This principle may apply to antibodies against other homopolysaccharide
antigens including levans, and may hold equally well with heteropolysaccha-
rides.J. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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Previous precipitin inhibition data (55) suggested that myeloma proteins
W3129 and QUPC 52 differed in the extents of their complementary regions for
isomaltose oligosaccharides, with combiningsites forfive and six glucose residues
respectively. These interpretations were based on the assumptions that terminal
nonreducing ends of isomaltose oligosaccharides were immunodominant for both
proteins, and that both had binding constants for IM6 of about 105 M-1 (AF' _
-7,000 cal/mol) . The present results show these assumptions are correct for
protein W3129 but not for protein QUPC 52 . With protein W3129 equilibrium
dialysis and fluorescence titrations establish that maximum complementarity is
for IM5 and that 55-60% of the total binding energy is for the terminal
nonreducing glucose as represented by methyl aDglucoside (Table II). Isomaltose
and methyl a Dglucoside were equally active on a molar basis, although previous
results (55) had indicated that the inhibitory power of IM2 was intermediate
between methyl aDglucoside and IM3. The present findings (Table II) are
correct as earlier data (55) with IM2 were obtained with a sample found to
contain a small amount of IM3 as contaminant. Equilibrium dialysis experi-
ments with protein QUPC 52 showed that its binding constant forIM7 andIM6 is
only 8.4 x 10 3 M-1 and both dialysis displacement experiments and quantitative
precipitin inhibition data (Table 11) indicate that about 70% of the total binding
energy is for IM3 but almost none is for IM2 or methyl aDglucoside. Thus, the
terminal nonreducing glucose is not the immunodominant structure. These
findings suggest a terminal nonreducing specificity for protein W3129 and a
nonterminal specificity for protein QUPC 52. Quantitative precipitin reactions
with the polymer fractions of both proteins (Fig. 6,1 b andI d) andlinear dextran
D3 strongly support this surprising difference in reactivity. The high binding
affinity of protein W3129 for terminal nonreducing ends of isomaltose oligosac-
charides along with its inability to precipitate linear dextran D3 serves as an es-
sential control and establishes that linear dextran D3 reacts immunochemically
as a population of molecules each having a single nonreducing end.
The above findings and those with concanavalin A (51) make it almost certain
that precipitation of linear dextran is a valid assay for antidextrans which can
react with a (1 , 6)-linked nonterminal determinants . For heterogeneous
antidextrans composed of populations with terminal and nonterminal specifici-
ties, linear dextran molecules would be cross-linked by antibodies having
nonterminal specificities, and would provide an insoluble matrix for bringing
down some antibody with terminal specificity . Thus, the difference in antibody
N precipitated from an antiserum by a branched dextran vs . a linear dextran
should reflect the presence of antibodies with terminal specificities for dextran
chains, but it would not provide a quantitative estimate.
From the above reasoning, quantitative precipitin reactions indicate that
human antidextrans from different individuals can differ in their relative
contents of antibodies having terminal and nonterminal specificities . The
antidextrans from subject 1 appear to contain the largest fraction of molecules
with nonterminal specificity as linear dextran D3 and branched native dextran
B512 precipitate about the same amount of antibody N (Fig. 6, I e, II a to II k) .
Likewise, the antidextrans from subjects 20 (Fig. 6, I f) and 219 seem to have
large fractions of molecules with terminal specificities as the differences in450
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precipitation by branched native dextran compared to linear dextran are the
greatest . Rabbits immunized with IM3 or IM6 coupled to BSA also make
antibodies which precipitate linear dextran (Fig . 6, III a to III k) ; however, there
is a relatively great difference in the amounts of antibody precipitated by dextran
B512 and linear dextran D3 indicating that these sera contain sizeable fractions
of antibody having nonreducing terminal specificity for the isomaltosyl chains.
The finding that a fraction of antibodies induced by immunization with
IM3-CONH-BSA could react at nonterminal locations along dextran chains
suggests as a possibility that nonreducing terminal determinants might trigger
certain clones which synthesize antibodies having sites with high binding
affinities for terminal glucosyl residues, but which can also cross-react at
nonterminal locations along linear dextran chains . This seems reasonable as the
only distinguishing feature between terminal and nonterminal nonreducing
glucosyl residues would be the hydrogen atom on the number six hydroxyl group
of the terminal nonreducing glucose. This poses the question of why certain
combining sites, like that of protein W3129, react only with terminal determi-
nants and do not cross-react at nonterminal locations. The most obvious
explanation would be to imagine a combining site with terminal specificity as
having binding energy for isomaltosyl structures distributed in such a manner
that the terminal nonreducing glucose residue is held in a fixed location within a
partially enclosed space. This model would attribute terminal specificity to the
shape of the combining site and perhaps also to specific binding energy forunique
structural features of the terminal nonreducing sugar residue. A site with
nonterminal reactivity can be imagined as a groove or depression with binding
energy distributed in such a way that the terminal end of the determinant is not
held within a space into which only it can fit; sites with a relatively linear groove
or depression would be expected to bind less strongly as is observed for QUPC 52.
The existence of rabbit anti-IM3-CONH-BSA antibodies which precipitate
linear dextran D3 might also be accounted for if structures as short as [a DGIc-
(1 ,6) a DGlc-OCH,(CHOH),-CONH-] are capable of presenting antigenic deter-
minants with immunodominant groups which do not involve the entire terminal
nonreducing glucosyl residue.
An unexpected finding with the human antidextrans (Fig. 6, 1 e to g) and
rabbit antisera against IM3 and IM6 coupled to BSA (Fig. 6, III a to k) was that
clinical dextran N-150N reacted more like linear dextran D3 than did native
dextran B512 which has more branches. By contrast, clinical dextran N-150N but
not linear dextran D3 was precipitated by protein W3129 (Fig. 6, 1 a and I b) . An
explanation for this apparent discrepancy emerges from the structures of these
dextrans. Clinical dextran N-150N has a mol wt of about 60,000 and comes from
mild acid hydrolysis of native dextran B512 which has a molecular weight in the
millions (61, cf. 4) . Both dextrans have about 4% branching due to a (1 --i 3)
linkages . The lengths of side chains for dextran B512 have been studied (80) and
about 40% are single glucosyl residues in a (1 -+ 3) linkage to the a (1 , 6) linked
backbone, while at least 45% are only two glucosyl residues long [aDGlc (1 , 6)
aDGlc (1 , 3)-]. These short chains may not function as antigenic determinants
for combining sites with terminal specificity for five or six glucosyl residues in a
(1 --> 6) linkage. A maximum of 15% of the side chains are thought to be longerJ. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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than two glucoses and in the present discussion these will be considered as
nonreducing terminal determinants. Thus, an average molecule of dextran B512
with mol wt of 10 x 108 would contain 60,000 glucosyl residues, 2,400 branch
points, and about360 side chains which could function as terminal determinants.
Assuming that clinical dextran has about the same side chain distribution as
dextran B512, then an average molecule of dextran N-150N (mol wt = 60,000)
would be composed of400 glucosyl residues, 16 branch points with a maximum of
but two or three which could function as terminal determinants. Thus, dextran
N-150N would have an abundance ofnonterminal determinants but would seem
to be deficient in terminal determinants . Moreover, antibodies with terminal
specificity could be blocked from reacting with dextran N-150N by antibodies
having nonterminal specificity but which react near the termini; the reverse
would not be true. Accordingly, the quantitative precipitin reactions ofheteroge-
neous antibodies with clinical dextran N-150N would appear to be more like
those of linear dextran than those ofa branched native dextran and the findings
(61, 62, 67) that antidextrans from different individuals differ in the percentages
of antibody precipitated by low molecularweight compared with native dextrans
would appear to be related to their contents of antibodies with terminal
specificities. Moreover, a fraction of antibody from Type II antipneumococcal
serum cross-reacts with dextrans and, as with human antidextrans, the cross-
reactive fraction gives reduced precipitation with low molecularweight dextrans
(11). This suggests that cross-reactions between Type II antipneumococcal sera
and dextran might occuratbothterminal andnonterminal locations. Finally, the
conclusion (48) thatrabbit antisera against a B512 dextran of mol wt 4,400 lacked
antibodies with terminal specificities may require modification as it was based
only on the similarity ofreactions between a linear dextran anda clinical dextran
(mol wt = 40,000). With a homogeneous myeloma protein like W3129 which has
50 to 60% ofitsbindingenergy directed againsttheterminal nonreducingglucose,
the limited branching of N-150N proved adequate for precipitation.
It is significant that the IM3 and IM6 eluates of antidextran 20 D3 differed in
the fraction oftotal antibody N which was precipitated by low molecular weight
dextrans (63). With 20 Dg-IM3Ab, dextran fraction NRC 1 (mol wt = 10,600)
precipitated about half the antibody N which was precipitable with dextran
fraction NRC 7 (mol wt = 225,000), but with 20 D3-IM6 Ab the values were
nearly the same. Thus, in addition to separating antidextrans into populations
which differ in the extent of their complementary regions for isomaltose
oligosaccharides (36, 63, 64, 65, 68, cf. 4, 5), sequential elution with IM3 and IM6
might also tend to fractionate antidextrans into populations which are enriched
with antibodies having terminal and nonterminal specificities respectively.
Indeed, with mixtures ofantibody populations having bindingproperties similar
to those of proteins W3129 or QUPC 52 (Table II), IM3 would be expected
preferentially to elute molecules like W3129 from Sephadex G75 and leave
molecules like QUPC 52 for elution with IM6.
Antigenic determinants for a (1 ~6)-specific human antidextrans can involve
as many as six and perhaps seven glucosyl residues and thenonreducing endhas
been thought to be immunodominant, thus making the greatest individual
contribution to binding and specificity (36, 39, 44, 45 cf. 4, 5). The combiningsite452
￿
BINDING PROPERTIES OF IMMUNOGLOBULIN COMBINING SITES
of protein W3129 is of this type and has the terminal nonreducing a-linked
glucosyl residue as its immunodominant group. This would be bound at one end
of the combining site, and IM5, which is the shortest oligosaccharide showing
maximum binding (Table 11), serves to measure the extent ofthecomplementary
region. The immunodominant group for protein QUPC 52 is not expressed by
structures smaller than IM3 and could require contributions from a nonterminal
residue, portions of both adjacent pyranose rings and the adjoining a (1 , 6)
linkages . Moreover, for combining sites with nonterminal specificity the subsite
which binds the immunodominant group could occur at one end of the groove or
in the middle. Isomaltose oligosaccharides larger than IM3 but smaller than the
entire antigenic determinant, which could form the immunodominant group in
more than one way, would be expected to occupy positions within the site which
result in maximum binding energies . Thus, the findings that IM5 is slightly less
active than IM6 which has the same binding constant as IM7 (Table 11) suggest
that maximum complementarity exists for five or six glucosyl residues ; however,
parts ofboth terminal nonreducing and reducing glucoses may not participate in
binding. If the QUPC 52 site were smaller there would be many ways for haptens
to enter as the chain got longer and hence the increment of increase in binding
activity should not decrease progressively with increasing chain length. The
immunodominant group for the heterogeneous antidextrans from subject 1
appears to involve two adjacent glucosyl residues and the adjoining a (1 ~ 6)
linkage. This interpretation is favored by the findings that these antidextrans
have mainly nonterminal specificity and that the AF' for IM2 is approximately
-4,000 to -4,500 cal/mol while methyl aDglucoside binds with only about -1,400
cal/mol (Table 11). Moreover, as pointed out earlier, the estimated binding
energy for methyl a Dglucoside may be excessive. Thus, different structures in a
chain of a (1 - 6)-linked glucosyl units can be recognized as the immunodomi-
nant group and some appear to require contributions from more than a single
residue.
The presentfindings aid in the interpretation ofearlierquantitative precipitin reactions
with various dextrans (55). Protein W3129 reacted equally with dextrans rich in a (1 -i6)
linkages andwiththose having high contents ofa (1 -+ 4)-like and a (1 -"6) linkageswhile
dextrans with high contents of a (1 -. 3)-like and a (1 -" 6) linkages were somewhat less
efficient at precipitating.ProteinQUPC 52 reactedbest withthea (1 --,6)-linked dextrans
but poorly with those having relatively high contents ofa (1 -. 4)-like and a (1 -" 3)-like
linkages in addition to a (1 -+ 6) linkages. The greater reactivity of protein W3129 over
protein QUPC 52 with dextrans high in non a (1 - 6) linkages would be accounted for if
many branches initiatedby non a (1 -6) linkages were shorterthan threea (1-.6)-linked
glucosyl residues . These probably could provide determinants for proteinW3129 but with
protein QUPC 52 short branches would decrease the reactivity of the internal a (1 -. 6)-
linked backbone. This is illustratedwith dextranB1299-S-3, which contains 50% a (1 -+ 4)-
like linkages as determined from periodate oxidation (81) and which was also found to
precipitate better than expected with various a (1 - 6)-specific human antidextrans (37
cf. 4). Methylation data (82) with this dextran indicated a high degree of branching by
a (1 - 2) linkages with one-third of the anglucopyranosyl residues existing at branch
points, one-third as nonreducingendgroups, and the remainderas nonterminal residues in
glycosidic linkage through carbons 1 and 6 (26%) or 1 and 3 (7%). Protein W3129, which
requires a single terminal nonreducing a-linked glucosyl residue for its immunodominantJ. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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group, precipitates as well with dextran B1299-S-3 as with branched dextrans high in
a (1 -" 6) linkages (55). The a (1 - 6)-specific antidextrans from subject 1, for which two
glucosyl residues are thought to form the immunodominant structure, give quantitative
precipitin reactions with dextran B1299-S-3 which are intermediate between those of
dextrans containing greater than 70% a (1 -" 6) linkages and that of dextran B1355-S-4
which has a high content of a (1 - 3)-like linkages and reacts poorly (37 cf. 4) . Protein
QUPC 52, which requires three glucosyl residues to form its immunodominant group,
reacts poorly and the same with dextrans B1299-S-3 and B1355-S-4 (55). Thus, the
abilities of these proteins to precipitate the highly branched dextran B1299-S-3 are cor-
related with the number of glucosyl residues needed to form the respective immuno-
dominant structures. This suggests that the sites of protein W3129, the human
antidextrans, and possibly protein QUPC 52 are able to bind dextran molecules at
branches that form the proper immunodominant structures but which may be shorter
than entire antigenic determinants of five or six sugar residues. Studies with a (1 -~ 6)-
specific human antidextrans also have identified dextran B742L-R with 81% a (1 -" 6)
linkages, as behaving anomalously in that it failed to precipitate as well as other dextrans
having greater than 70% a (1 -. 6) linkages (37 cf. 4) . This was suggested to result from
short branches occurring near nonreducing termini (37, 42 cf. 4). The findings that dextran
B742L-R displayed less than expected reactivity with myeloma proteins W3129 and
QUPC 52 (55) would require that short branches of perhaps single glucosyl residues also
occur along interior a (1 -~ 6)-linked chains . An alternative possibility would be the
occurrence of interior a (1 --~ 4)-like linkages which do not form branch points but instead
interrupt a (1 - 6) -linked chains so as to limit nonterminal binding without increasing the
number of terminal nonreducing determinants. Similarly, with both myeloma proteins
(55) and various a (1 -" 6)-specific human antidextrans (37 cf. 4) the low reactivity of
dextran B1355-S-4 could result in part from internal a (1 -. 3)-linked residues which are
not involved in branching (83) .
Certain data with fructosan-reactive myeloma proteins (54, 55) and human antilevans
(55, 84) are consistent with terminal and nonterminal specificities for levan chains.
Proteins W3082 and UPC 61 which are probably identical and different from protein J606
(54, 55, 60) all have been shown to have,6 (2 - 1) specificity but are thought to cross-react
at the nonreducing ends of ,8 (2 -. 6)-linked fructosyl chains in levan (55). The two
identical proteins have at least 50% of their binding energy for terminal nonreducing
,B-linked fructose as shown from fluorescence titrations with sucrose (Table 11) . This
estimate might have been higher if methyl oDfructoside were available as the nonreducing
glucose in sucrose may have interfered with binding. Also, all three proteins give virtually
no precipitation with rye grass levan (54, 55) which is composed of about 25-30 fructose
residues (85) joined almost entirely by ,8 (2 - 6) linkages (85, 86) and would thus be nearly
linear. Proteins UPC 10 and Y5476 are thought to have 0 (2 - 6) specificity because of
their reactions with levans and not with inulin which is ,B (2 --y 1)-linked (55) . These
proteins precipitate well with rye grass levan and this would be most easily accounted for
if they react at nonterminal locations on the ,d (2 -+ 6)-linked chain. A fraction of the
antilevan from subject 1 also precipitates with rye grass levan (55, 84) and this could result
from precipitation of antilevans with nonterminal specificity leaving most of the
antibodies with terminal specificity in the supernate. Large amounts (100,mol) of sucrose
(55), which would be expected to present a nonreducing J-linked fructose, do not inhibit
precipitation by the ,B (2 -" 6)-specific proteins which suggests that the immunodominant
structures require a contribution from more than a single fructosyl residue.
Myeloma proteins which can be considered as having terminal specificities for
a (1 , 6)-linked dextran chains (W3129), ,B (2 -. 1)-linked fructosan chains
(W3082 and UPC 61) (55) and /3 (1 , 6)-linked galactan chains (X-24 and J539)454
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(58, 59), all have binding constants slightly greater than 105 M` and are similar
in the way binding energy is directed against successive sugar residues in their
corresponding antigenic determinants (Table 11). Especially striking is the
finding that each protein has about -4,000 cal/mol for its terminal nonreducing
sugar residue properly linked. Protein QUPC 52 which has a much lower binding
constant than the other myeloma proteins and has nonterminal specificity also
has about -4,000 cal/mol for IM3, the smallest oligosaccharide tested that could
form the immunodominant structure. The significance of these similarities in
binding is unclear but they could result from common mechanisms for the
binding by myeloma proteins and antibodies as well as from architectural
similarities among combining sites specific for various oligosaccharide determi-
nants.
Crystallographic studies on the combining sites of myeloma proteins or
antibodies specific for nonterminal and for terminal carbohydrate determinants,
the architecture of the two types of combining sites, and the relative contribu-
tions of the shapes of thesites and of the contacting residues to the bindingwould
contribute materially to our knowledgeof antibody structureandspecificity . The
finding of myeloma antibodies with homogeneous binding sites ofone or the other
of these two kinds of sites supports the concept that they represent monoclonal
proteins selected from a large population of lymphoid cells each synthesizing a
specific antibody. It would be of considerable importance to develop methods for
separating these two kinds of antibody and studying their isoelectric spectra and
heterogeneity.
Summary
Binding constants of the dextran-reactive BALB/c mouse IgA myeloma
proteins W3129 and QUPC 52 have been determined for each member of the
isomaltose series of oligosaccharides and for methyl aDglucoside. Protein W3129
has maximum complementarity for isomaltopentaose (IM5) (AF' _ -7,180
cal/mol) with 55-60% of the total binding energy directed against methyl
aDglucoside. Protein QUPC 52 gives maximum binding with isomaltohexaose
(IM6) (OF° = -5,340 cal/mol) and has about 70% of its total binding energy for
isomaltotriose (IM3), but at most only 5% for isomaltose (IM2) or methyl
aDglucoside. Protein W3129 precipitates with branched dextrans high in a (1 , 6)
linkages and reacts with but does not precipitate a synthetic a (1 - 6)-linked
linear dextran. Protein QUPC 52 precipitates both branched and linear dextrans.
Thus, the immunodominant group for protein W3129 is mimicked by methyl
aDglucoside and this protein reacts exclusively at the terminal nonreducing ends
of a (1 , 6)-linked dextran chains . Protein QUPC 52 has an immunodominant
group which is expressed by IM3 but not smaller oligosaccharides and this
protein can react at nonterminal locations along a (1 - 6)-linked dextran chains.
Precipitation of linear dextran seems to be a valid although not quantitative
assay for antidextrans with nonterminal specificity . Quantitative precipitin
reactions with branched and linear dextrans suggest that a (1 ~ 6)-specific
human antidextrans are mixtures of molecules having terminal and nonterminal
specificities and that the fraction of each type can vary among individuals.
Rabbit antisera against IM3 or IM6 coupled to bovine serum albumin alsoJ. CISAR, E. A. KABAT, M. M. DORNER, AND J. LIAO
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appear to contain antibodies with nonterminal specificity for dextran chains
although a large fraction has terminal specificity. Low molecular weight clinical
dextran N-150N ( ~--e 60,000) reacted more like linear dextran than like its parent
native-branched dextran B512 . This is thought to result from an abundance of
nonterminal determinants in clinical dextran N-150N but a very small number of
functional terminal determinants per molecule. An appreciation of terminal and
nonterminal specificities and of the different immunodominant structures in
isomaltosyl chains has proven to be of great value in understanding the
immunochemical reactions of dextrans. Moreover, certain previous findings with
fructosan-reactive mouse myeloma proteins and human antilevans (55, 84) also
suggest terminal and nonterminal specificities for levan chains .
Received for publication 6 May 1975.
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